A dual SphK1/SphK2 inhibitor, called SphKI-II, enhances the sensitivity of HCC cells to 5-Fluorouracil (5-FU) and reduces cell proliferation and migration as well as inducing apoptosis [80]. The gene discussed is SPHK1; the disease is hepatocellular carcinoma.